FINWIRES · TerminalLIVE
FINWIRES

Protagonist Therapeutics Opts Out of Rusfertide US Profit-Sharing Arrangement With Takeda Pharmaceutical

By

-- Protagonist Therapeutics (PTGX) exercised its right to opt out of the 50/50 US profit and loss sharing arrangement under its global license and collaboration agreement with Takeda Pharmaceutical (TAK) for rusfertide, Protagonist Therapeutics said Tuesday.

As a result, Protagonist Therapeutics will be eligible to receive up to $400 million in opt-out payments.

The company will also be entitled to a $75 million milestone payment upon rusfertide's approval in the US and up to $975 million in other milestone payments and tiered royalties on net sales, according to the statement.

Takeda Pharmaceutical now holds exclusive development and commercialization rights to rusfertide in the US.

Rusfertide is under FDA Priority Review in the US for the treatment of adult patients with polycythemia vera, Protagonist Therapeutics said.

Price: $99.31, Change: $+0.84, Percent Change: +0.85%

Related Articles

Australia

Velo3D Closes $50 Million Registered Direct Offering

Velo3D (VELO) said Tuesday it closed an underwritten registered direct offering of nearly 3.6 million common shares for gross proceeds of about $50 million.Net proceeds will be used for working capital and general corporate purposes, the company added.Price: $13.76, Change: $-0.57, Percent Change: -3.98%

$VELO
Australia

First Financial Bankshares Ups Quarterly Dividend 15.8% to $0.22 a Share, Payable July 1 to Holders of Record June 12

Price: $32.61, Change: $+0.18, Percent Change: +0.56%

$FFIN
Mining & Metals

First Atlas Resources Sells MacKenzie East Claims in Quebec to LaFleur Minerals

First Atlas Resources (HHE.CN) on Tuesday said it agreed to sell a 100% interest in its MacKenzie East Claims located in the Val-d'Or gold camp, Quebec, to LaFleur Minerals (LFLR.CN) in a cash and stock deal.LaFleur will buy the property in exchange for $30,000 in cash, and 175,000 shares of LaFleur Minerals. The cash portion is payable within 48 hours of execution of the agreement, the company said.The share consideration will be issued upon receipt of exchange acceptance or, if not required, within five business days following closing of the deal. The property consists of 46 mineral claims covering about 1,781 hectares.The deal allows First Atlas to monetize a non-core asset while retaining exposure to the upside of the Val-d'Or region through its equity interest in LaFleur, it added.Shares of First Atlas were last seen down $0.005 to $0.10 on the Canadian Securities Exchange.

$HHE.CN$LFLR.CN